SCHEMBL3215499

SCHEMBL3215499

Cc1ccc(C=O)n1Cc1ccc(Cl)cc1Cl

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
VDR P11473 1/20 0.49
HPGD P15428 2/20 0.44
NPSR1 Q6W5P4 2/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
TSHR P16473 2/20 0.44
LMNA P02545 4/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
KDM4E B2RXH2 3/20 0.40
TDP1 Q9NUW8 2/20 0.40
NPC1 O15118 2/20 0.40
CYP2A13 Q16696 1/20 0.40
HTT P42858 1/20 0.40
RAB9A P51151 1/20 0.40
ALDH1A1 P00352 3/20 0.40
POLB P06746 2/20 0.40
MAPT P10636 1/20 0.40
ALOX12 P18054 1/20 0.40
CYP1A2 P05177 2/20 0.39
CYP2C9 P11712 2/20 0.39
CYP2C19 P33261 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3198916 0.81 TBXA2R (0.49) VDRHPGDNPSR1L3MBTL1TSHR
SCHEMBL3198904 0.81 TBXA2R (0.49) VDRHPGDNPSR1L3MBTL1TSHR
SCHEMBL31590884 0.80 VDR (0.49) VDRNPSR1L3MBTL1LMNASMN1; SMN2
SCHEMBL6180454 0.79 VDR (0.49) VDRHPGDNPSR1L3MBTL1TSHR
SCHEMBL3204053 0.78 HPGD (0.52) VDRHPGDNPSR1L3MBTL1TSHR
SCHEMBL6181231 0.73 VDR (0.52) VDRHPGDNPSR1L3MBTL1TSHR
SCHEMBL6181220 0.71 VDR (0.50) VDRHPGDNPSR1L3MBTL1TSHR
SCHEMBL31590716 0.71 ALDH1A1 (0.46) NPSR1L3MBTL1LMNASMN1; SMN2KDM4E
SCHEMBL6491398 0.71 VDR (0.49) VDRHPGDNPSR1L3MBTL1TSHR
SCHEMBL18627887 0.71 VDR (0.38) VDRLMNATDP1HTTPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100041892-A1 Therapeutic agent for diabetes ABE HIDENORI 2010-02-18 US disclosed
US-20090270631-A1 Therapeutic agent for diabetes ABE HIDENORI 2009-10-29 US disclosed
EP-1912645-A2 THERAPEUTIC AGENT FOR DIABETES Takeda Pharmaceutical Company Limited (JP) 2008-04-23 EP disclosed
US-20080009530-A1 Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-01-10 US disclosed
WO-2007018314-A2 THERAPEUTIC AGENT FOR DIABETES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-02-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270631-A1 Therapeutic agent for diabetes FABP4, SLC5A1, SLC5A2 VDR 978/4885HPGD 1030/4885NPSR1 1882/4885
US-20080009530-A1 Therapeutic Agent for Diabetes FABP4, SLC5A1, SLC5A2 VDR 864/4885HPGD 811/4885NPSR1 1130/4885
US-20100041892-A1 Therapeutic agent for diabetes FABP4, SLC5A1, SLC5A2 VDR 978/4885HPGD 1030/4885NPSR1 1882/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.